PharmEste s.r.l. is a biopharmaceutical company.
PharmEste s.r.l., a biopharmaceutical company, engages in the discovery and development of transient receptor potential (TRP) channel therapeutics for the treatment of neuropathic pain, overactive bladder, and other TRP-mediated diseases. It develops PHE377, a TRPV1 antagonist for the treatment of neuropathic pain.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 1, 2011 | Series B | €4.80M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
MPS Venture | — | Series B |